P53 and p73 in suppression of Myc-driven lymphomagenesis

International Journal of Cancer

Volumn 124, Issue 2, 2009, Pages 502-506

  Griesmann, Heidi ^a   Schlereth, Katharina ^a   Krause, Michael ^a   Samans, Birgit ^a   Stiewe, Thorsten ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Lymphoma; Myc; P53; P73; Tumor suppression

Indexed keywords

MYC PROTEIN; PROTEIN P53; PROTEIN P73; DNA BINDING PROTEIN; NUCLEAR PROTEIN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HETEROZYGOSITY LOSS; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; REAL TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; ALLELE; ANIMAL; APOPTOSIS; C57BL MOUSE; DNA MICROARRAY; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ALLELES; ANIMALS; APOPTOSIS; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LOSS OF HETEROZYGOSITY; LYMPHOMA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 58249089039     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23978     Document Type: Article

References (25)

1. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc induced lymphomagenesis. Genes Dev 1999;13:2658-69.
2. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 1999;13: 2670-7.
3. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 2002;1:289-98.
4. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809-19.
5. Jost CA, Marin MC, Kaelin WG, Jr. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 1997; 389:191-4.
6. Stiewe T. The p53 family in differentiation and tumorigenesis. Nat Rev Cancer 2007;7:165-8.
7. Beitzinger M, Hofmann L, Oswald C, Beinoraviciute-Kellner R, Sauer M, Griesmann H, Bretz AC, Burek C, Rosenwald A, Stiewe T. p73 poses a barrier to malignant transformation by limiting anchorage-independent growth. EMBO J 2008;27:792-803.
8. Zaika A, Irwin M, Sansome C, Moll UM. Oncogenes induce and activate endogenous p73 protein. J Biol Chem 2001;276:11310-6.
9. Stiewe T, Putzer BM. Role of the p53-homologue p73 in E2F1 induced apoptosis. Nat Genet 2000;26:464-9.
10. Soengas MS, Lowe SW. p53 and p73: seeing double? Nat Genet 2000;26:391-2.
11. Oswald C, Stiewe T. In good times and bad: p73 in cancer. Cell Cycle 2008;7:1726-31.
12. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F, Caput D. p73 deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000;404:99-103.
13. Perez-Losada J, Wu D, DelRosario R, Balmain A, Mao JH. p63 and p73 do not contribute to p53-mediated lymphoma suppressor activity in vivo. Oncogene 2005;24:5521-4.
14. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D, Yang A, McKeon F, Jacks T. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005;7:363-73.
15. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL. The c-myc oncogene driven by im- munoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985;318:533-8.
16. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Jr, Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-21.
17. Martinez-Delgado B, Melendez B, Cuadros M, Jose Garcia M, Nomdedeu J, Rivas C, Fernandez-Piqueras J, Benitez J. Frequent inactivation of the p73 gene by abnormal methylation or LOH in non-Hodg- kin's lymphomas. Int J Cancer 2002;102:15-19.
18. Corn PG, Kuerbitz SJ, van Noesel MM, Esteller M, Compitello N, Baylin SB, Herman JG. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. Cancer Res 1999;59:3352-6.
19. Hsu B, Marin MC, el-Naggar AK, Stephens LC, Brisbay S, McDonnell TJ. Evidence that c-myc mediated apoptosis does not require wild-type p53 during lymphomagenesis. Oncogene 1995;11:175-9.
20. Petrenko O, Zaika A, Moll UM. deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol Cell Biol 2003;23:5540-55.
21. Watanabe K, Ozaki T, Nakagawa T, Miyazaki K, Takahashi M, Hosoda M, Hayashi S, Todo S, Nakagawara A. Physical interaction of p73 with c-Myc and MM1, a c-Myc-binding protein, and modulation of the p73 function. J Biol Chem 2002;277:15113-23.
22. Uramoto H, Izumi H, Ise T, Tada M, Uchiumi T, Kuwano M, Yasumoto K, Funa K, Kohno K. p73 Interacts with c-Myc to regulate Y- box-binding protein-1 expression. J Biol Chem 2002;277:31694-702.
23. Senoo M, Manis JP, Alt FW, McKeon F. p63 and p73 are not required for the development and p53-dependent apoptosis of T cells. Cancer Cell 2004;6:85-9.
24. Vikhanskaya F, Toh WH, Dulloo I, Wu Q, Boominathan L, Ng HH, Vousden KH, Sabapathy K. p73 supports cellular growth through c- Jun-dependent AP-1 transactivation. Nat Cell Biol 2007;9:698-705.
25. Talos F, Nemajerova A, Flores ER, Petrenko O, Moll UM. p73 suppresses polyploidy and aneuploidy in the absence of functional p53. Mol Cell 2007;27:647-59.